EPA Emerging Pathogens Bulletin – EPA Disinfectants for Coronavirus disease 2019 (COVID-19), caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has been designated as an emerging pathogen.

What is an emerging pathogen?

Emerging infectious diseases are those whose incidence in humans has increased in the past 2 decades or threaten to increase in the near future. These diseases, which respect no national boundaries, can challenge efforts to protect workers as prevention and control recommendations may not be immediately available.

CDC page is: [https://www.cdc.gov/niosh/topics/emerginfectdiseases/default.html](https://www.cdc.gov/niosh/topics/emerginfectdiseases/default.html)

Coronavirus disease 2019 (COVID-19), caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has been designated as an emerging pathogen. The EPA has published a list of products that have been approved for use.

The EPA just posted this list on their website (link below). This is a list of products that have been approved that have the appropriate kill claims and emerging pathogen language, and confirmed on their label.

An individual pesticide product may be marketed and sold under a variety of names. Alternative brand names have the same EPA Reg. No. as the primary product. You can identify them by their three-part EPA Reg. No. The first two parts of the EPA Reg. No. are those of the primary registrant, plus a third set of numbers that represents the Subregistrant’s ID number. For example, EPA Reg. No. 6839-349-70627 is Diversey’s subregistration of a product with an identical formulation and efficacy to the Lonza’s primary product with the EPA Reg. No. 6839-349.

The products listed are by the EPA under their registered name, thus causing some confusion.


6836-349 LONZAGARD RCS256 PLUS = Virex Plus
70627-58 OXY-TEAM™ DISINFECTANT CLEAENER = Oxivir Five 16
70627-60 OXIVIR™ WIPES Diversey, Inc. WIPE = Oxivir Tb Wipes

Please contact Diversey Customer Technical Support at (800)-558-2332, option 5 if there are any questions.